Samsung Engineering & Asset Management secured a 518.6 billion won ($380 million) contract to build a biopharmaceutical raw materials plant for Germany’s Sartorius AG in South Korea’s Songdo Free Economic Zone.
The Korean construction firm will handle the entire project process from front end engineering design to equipment procurement and construction for the campus, according to a company statement Monday. The facility is scheduled for completion by 2027.
Sartorius plans to use the new Songdo Campus to produce disposable containers for biopharmaceutical production, pharmaceutical membrane filters, and cell culture media. The site will also provide non-clinical contract research organization services.
The deal marks a significant expansion for Samsung E&A, allowing it to diversify beyond traditional biopharmaceutical plants into materials production facilities. It also adds another global client to the company’s portfolio in the competitive bio-manufacturing sector.
Executives from both companies, including Samsung E&A CEO Namgung Hong and Sartorius Korea Operations CEO Kim Duk-sang, attended the contract signing ceremony held March 21.
Sartorius, headquartered in Göttingen, Germany, is a major supplier of equipment and technologies for the biopharmaceutical industry, with operations in more than 30 countries.
